Anita Katharina Wagner, Dr.Pharm.
Co-Author
This page shows the publications co-authored by Anita Wagner and Christine Lu.
Connection Strength
3.285
-
Lu CY, Zhang F, Golonski N, Lupton C, Jeffrey P, Wagner AK. State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015. Value Health. 2018 06; 21(6):692-697.
Score: 0.826
-
Lu CY, Lupton C, Rakowsky S, Babar ZU, Ross-Degnan D, Wagner AK. Patient access schemes in Asia-pacific markets: current experience and future potential. J Pharm Policy Pract. 2015; 8(1):6.
Score: 0.684
-
Lu CY, Emmerick IC, Stephens P, Ross-Degnan D, Wagner AK. Uptake of new antidiabetic medications in three emerging markets: a comparison between Brazil, China and Thailand. J Pharm Policy Pract. 2015; 8(1):7.
Score: 0.684
-
Leopold C, Lu CY, Wagner AK. Integrating public preferences into national reimbursement decisions: a descriptive comparison of approaches in Belgium and New Zealand. BMC Health Serv Res. 2020 Apr 25; 20(1):351.
Score: 0.245
-
Lu CY, Zhang F, Wagner AK, Nekhlyudov L, Earle CC, Callahan M, LeCates R, Xu X, Ross-Degnan D, Wharam JF. Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer. Breast Cancer Res Treat. 2018 Aug; 171(1):235-242.
Score: 0.214
-
Hsu JC, Ross-Degnan D, Wagner AK, Zhang F, Lu CY. How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid? Clin Ther. 2015 Jul 01; 37(7):1420-1432.e1.
Score: 0.174
-
Sruamsiri R, Ross-Degnan D, Lu CY, Chaiyakunapruk N, Wagner AK. Policies and programs to facilitate access to targeted cancer therapies in Thailand. PLoS One. 2015; 10(3):e0119945.
Score: 0.172
-
Leopold C, Wagner AK, Zhang F, Lu CY, Earle CC, Nekhlyudov L, Ross-Degnan D, Wharam JF. Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans. Breast Cancer Res Treat. 2018 Sep; 171(2):449-459.
Score: 0.054
-
Wharam JF, Zhang F, Lu CY, Wagner AK, Nekhlyudov L, Earle CC, Soumerai SB, Ross-Degnan D. Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment. J Clin Oncol. 2018 04 10; 36(11):1121-1127.
Score: 0.053
-
Leopold C, Wagner AK, Zhang F, Lu CY, Earle C, Nekhlyudov L, Ross-Degnan D, Wharam JF. Erratum to: Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer. Breast Cancer Res Treat. 2016 11; 160(2):385.
Score: 0.048
-
Leopold C, Wagner AK, Zhang F, Lu CY, Earle C, Nekhlyudov L, Ross-Degnan D, Wharam JF. Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer. Breast Cancer Res Treat. 2016 07; 158(2):333-40.
Score: 0.047
-
Sruamsiri R, Wagner AK, Ross-Degnan D, Lu CY, Dhippayom T, Ngorsuraches S, Chaiyakunapruk N. Expanding access to high-cost medicines through the E2 access program in Thailand: effects on utilisation, health outcomes and cost using an interrupted time-series analysis. BMJ Open. 2016 Mar 17; 6(3):e008671.
Score: 0.046
-
Hsu JC, Lu CY, Wagner AK, Chan KA, Lai MS, Ross-Degnan D. Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study. Health Policy. 2014 Jun; 116(2-3):196-205.
Score: 0.039
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.